###### Strengths and limitations of this study

-   Emergency department visits and hospitalisation due to asthma exacerbation have been considered as important risk factors of asthma-related death, in addition to negatively impacting the medical costs.

-   This study is the first to report data on the use of healthcare resources and deaths following exacerbations based on guideline-recommended clinical pathways by using a nationwide emergency department database.

-   It was not possible to determine the severity of emergent symptom, because detailed information like the medications used in emergency departments was not available.

Introduction {#s1}
============

Asthma is a chronic disease accompanied by narrowing of the airways.[@R1] Globally, there are 300 million patients with asthma.[@R2] About 13.8 million disability-adjusted life years are lost annually due to asthma and this is 1.8% of the total global disease burden.[@R3] The disease burden of asthma is known to vary with the presence or the severity of exacerbation.[@R4] Exacerbation, especially severe exacerbation, can cause higher medical cost in patients with asthma.[@R5]

Severe exacerbations in patients with asthma can be life threatening and can exert a significant burden on not only patients but also on the society because of their negative impact on health-related quality-of-life and medical costs.[@R6] Based on the American Thoracic Society/European Respiratory Society recommendation, the definition of severe exacerbations should include at least one of the following: (1) exacerbations requiring (additional) use of systemic corticosteroids; (2) exacerbations requiring hospitalisation or emergency department (ED) visit and systemic corticosteroids due to asthma.[@R9] ED visits and hospitalisation, especially to the intensive care unit (ICU) for asthma have been considered as important risk factors for asthma-related death, in addition to having a huge impact on the medical cost.[@R6] Thus, investigating ED visits and hospitalisations for asthma is important to understand the disease burden of patients with asthma.

In the Global Initiative for Asthma (GINA) recommendation, if patients are presenting signs of severe exacerbation, immediate access or transfer to acute care facility (eg, ED) is strongly recommended. The decision to hospitalise or discharge is made after managing them in the acute care facility.[@R6] Most studies have examined the utilisation of healthcare resources following an exacerbation in a cross-sectional way.[@R8] They mostly present the proportion of patients who were hospitalised or visited EDs and outpatient clinics, but not the sequential proportion of healthcare resources used, such as the proportion of hospitalised cases following ED visits. It is, therefore, important to understand the healthcare utilisation and the consequences caused by exacerbation based on the clinical pathways in line with the GINA exacerbation management process.

We aimed to evaluate the demographics and clinical characteristics of emergent patients with asthma who visited EDs in Korea from 2014 to 2016 and assess the consequences of these visits.

Methods {#s2}
=======

Data source {#s2-1}
-----------

We conducted a nationwide, cross-sectional study by using the National Emergency Department Information System (NEDIS) data from 2014 to 2016. This included reports from 375, 403 and 408 EDs in 2014, 2015 and 2016, respectively. These data included demographic and clinical characteristics of the patients, time of their visits, means of arrival, ED discharge diagnosis codes based on the *International Classification of Diseases 10th Revision* (ICD-10) and consequences of the ED visits.

Study population {#s2-2}
----------------

We included ED visit cases which met all of the following criteria for the analysis: (1) cases with a main diagnosis code of asthma (ICD-10 code: J45 or J46); (2) cases recorded as an emergent symptom in EDs. We used the variable 'emergent symptom: yes/no' to find ED visit cases with an emergent symptom from the database. We defined asthma based on the diagnosis codes which were physician diagnosed, not self-reported. In addition, because the diagnosis codes were listed in order of importance, we identified cases with a main diagnosis code (ie, first-listed diagnosis code) of asthma.

Outcome measures {#s2-3}
----------------

We evaluated the demographics and clinical characteristics of emergent patients with asthma who visited EDs in Korea and analysed the consequences of these visits. The evaluated characteristics included age, sex, types of insurance, means of arrival, chief complaints and comorbidities. We defined comorbidities (ie, disease categories of Charlson Comorbidity Index[@R11] and chronic obstructive pulmonary disease (COPD)) based on the diagnosis codes. The consequences of the visit included discharge, transfer to another ED, death in ED, hospitalisation (general ward or ICU), death during hospitalisation and others (ie, missing or unknown). We further evaluated the hospitalised cases following an ED visit based on age groups, years, seasons or time of ED visits. Only the first change in disposition following an ED visit was included in the analysis of consequences.

Statistical analyses {#s2-4}
--------------------

The unit of analysis in this study was an ED visit, and not a patient because the patients' unique identifiers were not included in the data. While categorical variables were presented as numbers with percentages, continuous variables were presented as mean with standard deviations. The annual trends from 2014 to 2016 were tested using the linear-by-linear association test for categorical variables and analysis of variance for continuous variables and were presented as a p value for trend. A two-tailed p\<0.05 was considered statistically significant. All analyses were performed using IBM SPSS version 22.0 (SPSS Inc., Chicago, IL, USA) and SAS version 9.4 (SAS Inc., Cary, NC, USA).

Patient and public involvement {#s2-5}
------------------------------

This research was done without patient involvement. Patients were not invited to comment on the study design and were not consulted to develop patient relevant outcomes or interpret the results. Patients were not invited to contribute to the writing or editing of this document for readability or accuracy.

Results {#s3}
=======

Demographic and clinical characteristics {#s3-1}
----------------------------------------

During 2014 to 2016, 25 545 841 ED visits were recorded in the NEDIS, of which 77 883 visits had a main diagnosis of asthma (ICD-10 code: J45 or J46). Among these 77 883 ED visits, 75.40% (n=58 713) were identified as emergent cases and were used for the analysis as emergent asthmatic cases. The mean age was 44.19±27.17 years. The age groups of 0--11 and 12--17 years showed decreasing trends of ED visits during 2014 to 2016 (p\<0.05). In contrast, during the same period, the adult groups (age groups of 18--29, 40--49, 60--69 and ≥80 years) showed increasing trends of ED visits (p\<0.001 for all groups). While female accounted for 49.47% of the entire study population, they were 53.98% of the adult population (aged ≥18 years). The top five chief complaints of emergent patients with asthma were dyspnoea (53.69%), cough (11.62%), fever (3.36%), sputum (1.42%) and chest discomfort (1.09%). Among baseline comorbidities, COPD was 2.20% ([table 1](#T1){ref-type="table"}).

###### 

Demographic and clinical characteristics of emergency department visit cases with asthma-related emergent symptom from 2014 to 2016 in Korea

  --------------------------------------------------------------------------------------------------------------------------
  Variables                                Overall\          Years             P value\*                           
                                           (N=58 713)                                                              
  ---------------------------------------- ----------------- ----------------- ----------------- ----------------- ---------
  Age, mean in years (SD)                  44.19 (27.17)     42.04 (27.57)     44.94 (27.11)     45.34 (26.76)     \<0.001

  Age group                                                                                                         

   0--11                                   11 299 (19.24)    4130 (22.89)      3587 (18.30)      3582 (17.00)      \<0.001

   12--17                                  2765 (4.71)       903 (5.00)        935 (4.77)        927 (4.40)        0.005

   18--29                                  5672 (9.66)       1611 (8.93)       1868 (9.53)       2193 (10.41)      \<0.001

   30--39                                  5240 (8.92)       1578 (8.75)       1763 (8.99)       1899 (9.01)       0.366

   40--49                                  6530 (11.12)      1878 (10.41)      2165 (11.04)      2487 (11.8)       \<0.001

   50--59                                  7415 (12.63)      2240 (12.42)      2484 (12.67)      2671 (12.77)      0.295

   60--69                                  5778 (9.84)       1679 (9.31)       1916 (9.77)       2183 (10.36)      \<0.001

   70--79                                  7851 (13.37)      2397 (13.29)      2700 (13.77)      2754 (13.07)      0.477

   80+                                     6163 (10.50)      1626 (9.01)       2184 (11.14)      2353 (11.17)      \<0.001

  Female                                   29 043 (49.47)    8848 (49.10)      9829 (50.14)      10 356 (49.15)    0.995

   0--11                                   3770 (33.37)      1433 (34.70)      1167 (32.53)      1170 (32.66)      0.052

   12--17                                  1170 (42.31)      380 (42.08)       415 (44.39)       375 (40.45)       0.473

   18--29                                  2998 (52.86)      839 (52.08)       1035 (55.41)      1124 (51.25)      0.459

   30--39                                  2953 (56.35)      933 (59.13)       983 (55.76)       1037 (54.61)      0.008

   40--49                                  3248 (49.74)      982 (52.29)       1069 (49.38)      1197 (48.13)      0.007

   50--59                                  3523 (47.51)      1054 (47.05)      1198 (48.23)      1271 (47.23)      0.938

   60--69                                  2775 (48.03)      812 (48.36)       898 (46.87)       1065 (48.79)      0.723

   70--79                                  4410 (56.17)      1336 (55.74)      1572 (58.22)      1502 (54.54)      0.331

   80+                                     4196 (68.08)      1089 (66.97)      1492 (68.32)      1615 (68.64)      0.286

  Type of insurance                                                                                                 

   National Health                         51 028 (86.91)    15 724 (87.15)    17 009 (86.77)    18 295 (86.83)    0.369

   Medical Aid                             6611 (11.26)      1949 (10.80)      2225 (11.35)      2437 (11.57)      0.018

   Other†                                  1074 (1.83)       369 (2.05)        368 (1.88)        337 (1.60)        0.001

  Mode of arrival                                                                                                   

   Ambulance                               11 590 (19.74)    3473 (19.25)      3946 (20.13)      4171 (19.80)      0.201

   Walk                                    43 799 (74.6)     12 577 (69.71)    14 747 (75.23)    16 475 (78.20)    \<0.001

   Car                                     2952 (5.03)       1798 (9.97)       804 (4.10)        350 (1.66)        \<0.001

   Other‡                                  372 (0.63)        194 (1.08)        105 (0.54)        73 (0.35)         \<0.001

  Chief complaints§                                                                                                 

   Dyspnoea                                31 516 (53.69)    10 140 (56.20)    10 085 (51.45)    11 291 (53.59)    \<0.001

   Cough                                   6821 (11.62)      2251 (12.48)      2241 (11.43)      2329 (11.05)      \<0.001

   Fever                                   1972 (3.36)       701 (3.89)        540 (2.75)        731 (3.47)        0.044

   Sputum                                  835 (1.42)        232 (1.29)        292 (1.49)        311 (1.48)        0.124

   Chest discomfort                        639 (1.09)        177 (0.98)        226 (1.15)        236 (1.12)        0.203

   Wheezing                                492 (0.84)        164 (0.91)        171 (0.87)        157 (0.75)        0.072

   Dyspnoea acute                          446 (0.76)        158 (0.88)        123 (0.63)        165 (0.78)        0.351

   Chest pain                              415 (0.71)        134 (0.74)        144 (0.73)        137 (0.65)        0.266

   Asthma                                  365 (0.62)        145 (0.80)        123 (0.63)        97 (0.46)         \<0.001

   Abdominal pain                          268 (0.46)        115 (0.64)        78 (0.40)         75 (0.36)         \<0.001

  Comorbidities¶                                                                                                    

   Myocardial infarction                   82 (0.14)         16 (0.09)         24 (0.12)         42 (0.20)         0.003

   Congestive heart failure                575 (0.99)        132 (0.73)        183 (0.93)        260 (1.23)        \<0.001

   Peripheral vascular disease             21 (0.04)         9 (0.05)          3 (0.02)          9 (0.04)          0.772

   Cerebrovascular disease                 93 (0.16)         29 (0.16)         30 (0.15)         34 (0.16)         0.979

   Dementia                                62 (0.11)         15 (0.08)         23 (0.12)         24 (0.11)         0.365

   Chronic pulmonary disease\*\*           58 713 (100.00)   18 042 (100.00)   19 602 (100.00)   21 069 (100.00)   NC

   Rheumatic disease                       22 (0.04)         9 (0.05)          6 (0.03)          7 (0.03)          0.412

   Peptic ulcer disease                    77 (0.13)         50 (0.28)         17 (0.09)         10 (0.05)         \<0.001

   Mild liver disease                      97 (0.17)         24 (0.13)         43 (0.22)         30 (0.14)         0.901

   Diabetes without chronic complication   407 (0.70)        117 (0.65)        166 (0.85)        124 (0.59)        0.393

   Diabetes with chronic complication      51 (0.09)         14 (0.08)         19 (0.10)         18 (0.09)         0.814

   Hemiplegia or paraplegia                4 (0.01)          0 (0.00)          3 (0.02)          1 (0.00)          0.626

   Renal disease                           162 (0.28)        41 (0.23)         55 (0.28)         66 (0.31)         0.108

   Any malignancy††                        165 (0.28)        47 (0.26)         64 (0.33)         54 (0.26)         0.885

   Moderate or severe liver disease        4 (0.01)          0 (0.00)          1 (0.01)          3 (0.01)          0.086

   Metastatic solid tumour                 8 (0.01)          0 (0.00)          3 (0.02)          5 (0.02)          0.046

   AIDS/HIV                                0 (0.00)          0 (0.00)          0 (0.00)          0 (0.00)          NC

   Chronic obstructive pulmonary disease   1278 (2.20)       370 (2.05)        424 (2.16)        484 (2.30)        0.095
  --------------------------------------------------------------------------------------------------------------------------

\*P values were calculated for data from 2014 to 2016 with the linear-by-linear association test for categorical variables and analysis of variance for continuous variables. P values for some variables (chronic pulmonary disease and AIDS/HIV) could not be calculated because data from 2014 to 2016 were either 0 or 100%.

†Auto insurance, workers' compensation insurance and private insurance.

‡Aeroplane, bicycle and motorcycle.

§The top 10 most common chief complaints were listed. Multiple responses were allowed for this variable.

¶The comorbidities used all ED discharge diagnosis codes of the patient.

\*\*Chronic pulmonary disease can only be 100% because this disease category from Charlson Comorbidity Index included asthma diagnosis codes (J45/J46).

††Malignancy include lymphoma and leukaemia, except malignant neoplasm of skin.

NC, not calculated.

Consequences: overall {#s3-2}
---------------------

Following an ED visit, while 66.04% of the patients were discharged from the EDs, 31.69% were hospitalised, 0.10% died in EDs, 1.89% were transferred to other EDs and 0.29% were unknown or missing. Among the hospitalised cases after an ED visit, 89.88% were admitted to general wards, and 10.12% to ICUs.

Consequences: hospitalised cases after an ED visit {#s3-3}
--------------------------------------------------

The proportion of hospitalised cases based on age groups followed a U-shaped trend. In the age groups ≥70 years, more than half of the ED visit cases were hospitalised ([figure 1A](#F1){ref-type="fig"}). The number and proportion of deaths in the general wards and ICUs generally increased with age ([figure 1B](#F1){ref-type="fig"}).

![Number and proportion of (A) hospitalised cases and (B) deaths during hospitalisation following an emergency department (ED) visit according to age groups. ICU, intensive care unit.](bmjopen-2019-036237f01){#F1}

While the hospitalisation (total and general wards) case in the age group ≤11 years peaked in autumn, those in age group ≥50 years was predominantly in spring and winter ([figure 2A and B](#F2){ref-type="fig"}). Additionally, the hospitalisation of individuals ≥70 years to ICUs also peaked in spring and winter ([figure 2C](#F2){ref-type="fig"}). The ratio of ICU/general ward admission showed parallel seasonal trends in general ([figure 2D](#F2){ref-type="fig"}).

![Number and ratio of hospitalised cases following an emergency department visit by (A--D) season. ICU, intensive care unit.](bmjopen-2019-036237f02){#F2}

Based on the time of ED visits, the number of hospitalised cases (total, general wards and ICUs) varied between the different age groups. It peaked between 9:00 and 12:00 for the ≥60 years group ([figure 3A--C](#F3){ref-type="fig"}). The ratio of ICU/general ward admission at the arrival time of 0--3:00 in the ≥60 years group was the highest compared with all other times of visit and age groups ([figure 3D](#F3){ref-type="fig"}).

![Number and ratio of hospitalised cases following an emergency department (ED) visit by (A--D) time of ED visit. ICU, intensive care unit.](bmjopen-2019-036237f03){#F3}

Discussion {#s4}
==========

Of 58 713 ED visits, 31.69% were hospitalised and 0.10% died. The older they were, the more hospitalisation and death, and more patients died in general wards or ICUs. Depending on the season and time of ED visit, the number of hospitalisations, general wards and ICUs admission cases and ratio of ICU/GE admission differed by the patient's age.

As per the GINA recommendations, patients with severe asthmatic exacerbation should be managed first in an acute care facility such as an ED.[@R6] To the best of our knowledge, this is the first study that provides comprehensive information on the use of medical resources, as well as the incidence of deaths following asthmatic exacerbations based on the clinical pathway by using a nationwide ED database. In order to clarify the interpretation of the findings, we excluded patients who visited the ED with non-emergent symptoms from the analysis.

This study showed asthma exacerbation requiring ED visits occurred more in boys than girls aged under 18 years. In adults above 18 years, numbers of women with asthma who visited the ED were higher than the numbers of men. Different findings by age and sex were consistent with previous studies.[@R12]

Marked differences were noted in the hospitalised cases following an ED visit among older patients, especially those aged above 70 years compared with the patients who aged under 70 years. The proportion of hospitalised cases and the ratio of ICU/general ward admissions were much higher in older patients. In addition, nocturnal asthma symptoms were also more common in this group. Previous study reported that older patients who visited the ED for asthma had higher rates of healthcare utilisations.[@R15] Similarly, this real-world data showed the proportion of adult patients who were hospitalised after ED visit was higher in older patients. This could be because older patients are more likely to (1) be associated with modifiable risk factors for asthma exacerbation (eg, poor adherence, incorrect inhaler technique, smoking or comorbidities), and (2) have worsened lung or other physical functions (eg, immunity) and reduced response to antiasthmatics due to ageing or longer disease duration.[@R6] An increased exacerbation of asthma in older patients has been reported in previous studies, but this study has an additional significance as it reports on other aspects of increased exacerbation that were not previously reported, such as nocturnal symptoms.[@R13]

Limitations {#s4-1}
-----------

This study has several limitations. First, because detailed information regarding the medications used in EDs was not available, we could not determine if systemic corticosteroids were used for the emergent symptoms. However, by excluding patients with non-emergent asthma symptoms, we tried to minimise the impact of relatively mild exacerbations. Second, we were not able to define patients with asthma based on the detailed diagnostic criteria evaluated before ED visit (eg, previous spirometry evaluation records) and were not able to know asthma treatments prescribed for patients before ED visit. These kinds of information were not available in these NEDIS data. However, we tried to define patients with asthma by using the diagnosis codes which were listed as the main diagnosis when the patients visited EDs. Third, we were not able to evaluate patients' smoking history as baseline characteristics, because NEDIS data do not provide this information. Fourth, a unit of analysis in this study was an ED visit and not a patient, since the patients' unique identifiers were not available in the data. Thus, multiple ED visits by the same person could have been included in the analysis. Fifth, our study results may not be generalisable to other countries, with regard to the healthcare system and accessibility. Nevertheless, the use of large-scale ED visit data collected nationwide, from 408 EDs, is the major strength of this study.

Conclusions {#s5}
===========

We studied the characteristics of patients who visited EDs for asthma-related emergent symptoms, and the consequences of these visits, by using a nationwide ED database. We found that the ED visits by older patients resulted in more ICU admissions and poorer outcomes than that by other age groups. These results can contribute to a better understanding of medical resource utilisation in emergent patients with asthma. Because severe exacerbations are the most burdensome and potentially life-threatening events in patients with asthma, our findings are valuable in planning resource allocation to achieve optimal care for patients with asthma at the population level.[@R6]
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